☆ 4.7 Review

Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review Medicine, Research & Experimental

Therapeutic potential of CAR T cell in malignancies: A scoping review

Ali Zarezadeh Mehrabadi et al.

Summary: CAR-T cell therapy shows great potential in cancer treatment, but faces challenges in treating solid tumors. Combining with other therapeutic approaches may enhance the efficacy of CAR-T cells, but further research is needed to determine their safety and effectiveness.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹
Meeting Abstract Oncology

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA

Ghassan K. Abou-Alfa et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹
Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹
Article Oncology

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Heinz-Josef Lenz et al.

Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹
Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹
Article Chemistry, Multidisciplinary

Potential Application of Exosomes in Vaccine Development and Delivery

Md Nurul Huda et al.

Summary: This review summarizes the crucial role of exosomes in immune modulation, cell-cell communication, and disease progression, and discusses the potential of exosomes as vaccine delivery vehicles.

PHARMACEUTICAL RESEARCH (2022)

添加到收藏夹
Review Oncology

Novel Cellular Therapies for Hepatocellular Carcinoma

Harriet Roddy et al.

Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death globally. The current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers limited clinical benefit. Cellular immune therapies, such as CAR-T and TCR-T, are being explored as potential treatment options for HCC. Advanced engineering solutions are also being investigated to enhance the therapeutic approach.

CANCERS (2022)

添加到收藏夹
Review Pharmacology & Pharmacy

PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?

Alessandro Rizzo et al.

Summary: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy worldwide, resulting in millions of deaths annually. Despite important results from immune checkpoint inhibitors (ICIs), the identification of predictive biomarkers of response remains a high unmet need, highlighting the importance of reliable predictors for proper patient selection. Well-designed, multicenter clinical trials specifically focused on predictive biomarkers are warranted in this setting.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

添加到收藏夹
Review Oncology

Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights

Christo Kole et al.

Summary: This article presents the latest advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using a combination of immunotherapy with other interventions such as chemotherapy and/or radiation. The role of the tumor microenvironment as a barrier to immunotherapy efficacy is outlined, and the use of immunotherapy biomarkers to detect response is examined.

CANCER MANAGEMENT AND RESEARCH (2022)

添加到收藏夹
Review Oncology

The next wave of cellular immunotherapies in pancreatic cancer

Dannel Yeo et al.

Summary: Pancreatic cancer is a highly aggressive disease that is expected to become the second leading cause of cancer-related death worldwide. Current treatments for pancreatic cancer are limited, and cellular immunotherapy, particularly CAR T cell therapy, has shown limited efficacy. This review provides an overview of ongoing clinical studies and strategies to improve CAR T cell efficacy in pancreatic cancer.

MOLECULAR THERAPY-ONCOLYTICS (2022)

添加到收藏夹
Review Oncology

An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer

Maryum Nisar et al.

Summary: Chemotherapy resistance and the unique tumor microenvironment contribute to the difficulty in managing pancreatic cancer. Advanced immunotherapies, specifically oncolytic virus therapy, show promise in enhancing immune response and improving patient survival.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹
Review Biology

An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma

Eleni-Myrto Trifylli et al.

Summary: HCC and CCA are highly malignant forms of primary liver cancers. Carcinogenesis of hepatocellular and bile duct is a complex process influenced by genetic and epigenetic alterations, environmental factors, and the gut microbiome. Recent studies have identified the crucial role of intestinal microbiota in the pathogenesis and opened new possibilities for novel therapeutic strategies such as immunotherapy, improving the overall survival of cancer patients.

LIFE-BASEL (2022)

添加到收藏夹
Article Oncology

Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).

John Davelaar et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹
Review Biotechnology & Applied Microbiology

Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma

Jiaojiao Guo et al.

Summary: CAR-T therapy is a novel tumor immunotherapy that has shown promising outcomes in leukemia and lymphoma by enabling T cells to specifically recognize tumor-associated antigens through genetic engineering. However, challenges remain in treating hepatocellular carcinoma, and overcoming factors like tumor antigen heterogeneity, immunosuppressive microenvironment, and adverse reactions are crucial for enhancing the efficacy of CAR-T cells in HCC patients.

CANCER GENE THERAPY (2021)

添加到收藏夹
Article Oncology

Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer

Zelin Hou et al.

Summary: VISTA expression in tumor cells is associated with favorable prognosis in pancreatic cancer patients. The study showed that VISTA level is positively correlated with different immune cell subclusters in PDAC, and anti-VISTA therapy can effectively reduce metastatic nodules in mouse models with liver metastases of PDAC.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹
Review Medicine, General & Internal

Current immunotherapy in gastrointestinal malignancies A Review

Dushyant Singh Dahiya et al.

Summary: Immunotherapy is a highly specific treatment for cancer patients by stimulating or suppressing the immune system in a specific manner, in contrast to the non-specific traditional therapies available.

JOURNAL OF INVESTIGATIVE MEDICINE (2021)

添加到收藏夹
Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹
Review Oncology

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

Philippe Rochigneux et al.

Summary: The mortality of hepatocellular carcinoma (HCC) is rapidly increasing worldwide, and immunotherapy involving engineered T cells has shown promising results in clinical trials for combating liver cancer.

CANCERS (2021)

添加到收藏夹
Article Pharmacology & Pharmacy

Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer

Alessandro Rizzo et al.

Summary: The paper provides an overview of current status of immunotherapies for biliary tract cancer (BTC), discusses the pharmacology, safety and efficacy of anti-PD-L1 inhibitor durvalumab in treating BTC, and considers future research directions for this agent in this context.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹
Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian et al.

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

添加到收藏夹
Review Immunology

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

Karthik Dhatchinamoorthy et al.

Summary: Loss of MHC I antigen presentation is common in many cancers, which may impair immune responses and affect the efficacy of immunotherapy. Studies have discussed underlying mechanisms through which some cancers evade immune killing by shutting down the MHC I pathway, and proposed potential strategies to overcome this limitation.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Review Immunology

Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma

Zoe C. Schmiechen et al.

Summary: Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with low survival rates due to late diagnosis, early metastasis, and resistance to therapy. While there is evidence that immune cells can play a role in PDA, the tumor can evade immune responses through various mechanisms. Treatment strategies involving immunotherapy combinations are necessary to overcome resistance in PDA.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Article Oncology

Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer

Jill P. Smith et al.

Summary: Clinical studies have shown that immune checkpoint antibody therapy is effective for advanced gastric cancer patients, while the gastrin peptide can stimulate tumor growth through the CCK-BR receptor. In experimental models, a vaccine targeting the gastrin peptide (PAS) was able to inhibit tumor growth significantly.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹
Review Oncology

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Alessandro Rizzo et al.

Summary: Immune checkpoint inhibitors, particularly the combination of PD-L1 inhibitor and antiangiogenic agent, have emerged as novel systemic treatment options for advanced HCC. Despite this, reliable predictors of response to immunotherapy in HCC patients remain unanswered questions.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹
Review Oncology

Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy

Evangelos Koustas et al.

Summary: This review discusses the interplay between autophagy and cholangiocarcinogenesis, as well as preclinical studies on drugs that modulate autophagy to induce tumor cell death. The role of autophagy in promoting tumor cell survival, invasiveness, and resistance to chemotherapy is highlighted, along with the potential for designing novel therapeutic strategies targeting autophagy pathways in cholangiocarcinoma.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹
Review Gastroenterology & Hepatology

Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors

Alison P. Klein

Summary: Pancreatic cancer is a leading cause of cancer death globally, with significant risk factors including smoking, obesity, diabetes, and genetic factors. Efforts to understand and address these modifiable and inherited risk factors are crucial for early detection and prevention strategies for pancreatic cancer.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹
Article Biology

The Implication of Autophagy in Gastric Cancer Progression

Evangelos Koustas et al.

Summary: Gastric cancer is the fifth most common malignancy worldwide and many tumors display resistance to current chemotherapeutic agents. The interplay between gastric cancer development and the autophagy process is crucial, but the role of autophagy as either a tumor suppressor or promoter remains controversial.

LIFE-BASEL (2021)

添加到收藏夹
Article Oncology

First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos et al.

Summary: Subcutaneous injection of envafolimab showed good safety and pharmacokinetics, with promising antitumor activity in advanced solid tumor patients. It may be a more convenient option compared to currently approved intravenous PD-1/PD-L1 inhibitors.

ONCOLOGIST (2021)

添加到收藏夹
Review Immunology

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma

Oraianthi Fiste et al.

Summary: Biliary tract cancer, particularly intrahepatic cholangiocarcinoma (iCC), is a rare and highly aggressive malignancy with limited therapeutic options. Platinum-based chemotherapy is considered the gold standard for advanced disease management. Immunotherapy is emerging as a potential paradigm shift in the treatment of iCC, with ongoing research focusing on intrinsic tumor factors and the tumor microenvironment.

VACCINES (2021)

添加到收藏夹
Review Biochemical Research Methods

Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines

Ali Azadi et al.

Summary: Colorectal cancer is a heterogeneous disease characterized by genetic and epigenetic alterations. Immunotherapy combined with other treatments can enhance treatment efficiency. Current research on CRC immunotherapy focuses on therapeutic monoclonal antibodies and RNA vaccines.

BIOLOGICAL PROCEDURES ONLINE (2021)

添加到收藏夹
Review Biochemistry & Molecular Biology

Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis

Hui Wang et al.

Summary: Colorectal cancer (CRC) is a highly prevalent and lethal malignant tumor in the digestive system. Tumor-associated macrophages (TAMs) play a crucial role in various mechanisms of CRC progression, such as promoting tumor proliferation, invasion, angiogenesis, and immunosuppression, although their exact role is still debated in clinical evidence.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹
Meeting Abstract Oncology

Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

Osama E. Rahma et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹
Meeting Abstract Oncology

Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Gang Jin et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹
Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹
Review Immunology

Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications

Ding-Kang Wang et al.

Summary: Gastrointestinal cancer is a leading cause of cancer-related mortality, with immunotherapy becoming a hot research topic for its integrative management. Understanding cancer progression mechanisms and optimizing treatment strategies is crucial for improving outcomes in gastrointestinal cancer patients.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Review Oncology

Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?

Maria Gutierrez-Larranaga et al.

Summary: High expression levels of immune checkpoints in patients with cholangiocarcinoma (CCA) are associated with worse clinical outcomes, suggesting immune checkpoint inhibitors (ICIs) as potential therapeutic approaches. Combining different ICIs may enhance efficacy compared to monotherapy, and the combination of ICIs with other common therapies like chemotherapy shows promise for treating CCA patients.

LIVER CANCER (2021)

添加到收藏夹
Review Medicine, General & Internal

Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Junhee Pyo et al.

Summary: This study indicates that microsatellite phenotype and drug regimen are the primary factors influencing treatment responses among advanced/metastatic CRC patients treated with an ICI-based regimen.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹
Review Oncology

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer

Elisa Grassi et al.

Summary: 8-12% of patients with advanced colon rectal cancer present with BRAF alterations, particularly the V600E mutation, which is associated with poor prognosis. New therapeutic options, such as targeted therapy combinations, are emerging for this subgroup of patients. Treatment optimization for this subgroup is an important goal.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹
Article Gastroenterology & Hepatology

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Arndt Vogel et al.

Summary: The study aimed to evaluate the impact of lenvatinib versus sorafenib on health-related quality of life (HRQOL) in patients with unresectable hepatocellular carcinoma. The findings showed that lenvatinib group had generally favorable changes in most HRQOL scales compared to sorafenib group. Patients treated with lenvatinib experienced significant delays in deterioration in specific domains.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹
Review Immunology

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

Howard Donninger et al.

Summary: The emergence of cancer immunotherapy has brought new hope to cancer patients, although its effectiveness varies across different cancer types. Cancer vaccines offer an alternative method to balance the interaction between tumor cells and the host immune system.

VACCINES (2021)

添加到收藏夹
Review Medicine, General & Internal

Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis

Chunfang Tian et al.

Summary: High TIL density in H&E-stained sections is associated with better overall survival and less aggressive clinicopathological characteristics in patients with gastric cancer. However, TIL density was not correlated with age, gender, Lauren classification, or histological grade.

BMJ OPEN (2021)

添加到收藏夹
Review Biochemistry & Molecular Biology

Update of early phase clinical trials in cancer immunotherapy

Dae Ho Lee

Summary: Immunotherapy has become a standard pillar in cancer treatment, with immune checkpoint inhibitors and CAR T cells driving this success. However, resistance remains a challenge for many patients, leading to disease progression. Novel treatment options and combination approaches are being developed to better understand mechanisms of action and resistance, advance biomarker and therapeutic development, and overcome resistance in cancer patients.

BMB REPORTS (2021)

添加到收藏夹
Review Oncology

Current status of immunotherapy for advanced gastric cancer

Akihito Kawazoe et al.

Summary: Immune checkpoint inhibitors such as PD-1 and PD-L1 monoclonal antibodies have shown potential in treating AGC, but better patient selection and additional treatments are needed to overcome resistance.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹
Review Oncology

CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety

Huali Li et al.

Summary: CAR-T cell immunotherapy is a genetically engineered method to combat malignant diseases, showing progress in hematological malignancies but facing challenges in solid tumors like CRC. New approaches are proposed to overcome these challenges and improve the efficacy of CAR-T therapy in solid tumors.

JOURNAL OF CANCER (2021)

添加到收藏夹
Review Oncology

The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications

Ryota Tamura et al.

MEDICAL ONCOLOGY (2020)

添加到收藏夹
Article Oncology

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

Suneel D. Kamath et al.

ONCOLOGIST (2020)

添加到收藏夹
Review Oncology

Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory

Wenhao Luo et al.

CANCER CELL INTERNATIONAL (2020)

添加到收藏夹
Correction Biochemistry & Molecular Biology

Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway (vol 74, pg 2351, 2019)

Chao Liu et al.

CELL DEATH AND DIFFERENTIATION (2020)

添加到收藏夹
Article Oncology

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Li-Tzong Chen et al.

GASTRIC CANCER (2020)

添加到收藏夹
Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

Gut microbiome in HCC - Mechanisms, diagnosis and therapy

Robert F. Schwabe et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Review Oncology

Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis

Gabor Lendvai et al.

PATHOLOGY & ONCOLOGY RESEARCH (2020)

添加到收藏夹
Article Pathology

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features

Xiaoqiao Liu et al.

PATHOLOGY RESEARCH AND PRACTICE (2020)

添加到收藏夹
Review Medicine, Research & Experimental

Cancer immunotherapy: Pros, cons and beyond

Shuzhen Tan et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

添加到收藏夹
Article Biotechnology & Applied Microbiology

The Changing Epidemiology of Hepatocellular Carcinoma : Experience of a Single Center

Lydia Giannitrapani et al.

BIOMED RESEARCH INTERNATIONAL (2020)

添加到收藏夹
Review Immunology

Cancer vaccines: Targeting KRAS-driven cancers

Ying Zhang et al.

EXPERT REVIEW OF VACCINES (2020)

添加到收藏夹
Review Oncology

Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?

Yuwei Li et al.

CANCER MEDICINE (2020)

添加到收藏夹
Article Oncology

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Sarina A. Piha-Paul et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹
Article Oncology

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Richard D. Kim et al.

JAMA ONCOLOGY (2020)

添加到收藏夹
Review Biochemistry & Molecular Biology

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors

Evangelos Koustas et al.

BIOMOLECULES (2020)

添加到收藏夹
Review Oncology

The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis

Adile Orhan et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹
Review Oncology

Immunotherapy for pancreatic cancer: A 2020 update

Dimitrios Schizas et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹
Review Immunology

Myeloid-Derived Suppressor Cells in Colorectal Cancer

Izabela Sieminska et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹
Review Medicine, General & Internal

CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer

Dominika Bebnowska et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹
Article Cell Biology

Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models

Evangelos Koustas et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

添加到收藏夹
Review Cell Biology

Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy

Shunda Wang et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

添加到收藏夹
Review Oncology

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Adham S. Bear et al.

CANCER CELL (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹
Article Immunology

Mechanisms of immune escape in the cancer immune cycle

Sha Tang et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹
Review Immunology

IDO Expression in Cancer: Different Compartment, Different Functionality?

Annabel Meireson et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹
Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

添加到收藏夹
Review Oncology

A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)

Shuting Han et al.

CANCERS (2020)

添加到收藏夹
Review Gastroenterology & Hepatology

Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma

Clifford Akateh et al.

WORLD JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹
Article Multidisciplinary Sciences

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

Daniele Biasci et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹
Article Oncology

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients

Lawrence G. Lum et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹
Review Immunology

TIM3 comes of age as an inhibitory receptor

Yochai Wolf et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹
Review Immunology

Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Jung-Ho Kim et al.

IMMUNE NETWORK (2020)

添加到收藏夹
Article Oncology

EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions

Sho Sasaki et al.

GASTRIC CANCER (2019)

添加到收藏夹
Article Oncology

Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis

Cong Chen et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹
Review Oncology

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer

Aesha I. Ali et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹
Review Oncology

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Yoshihiro Ohue et al.

CANCER SCIENCE (2019)

添加到收藏夹
Meeting Abstract Oncology

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

Josep M. Llovet et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹
Review Immunology

Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

Steven S. Raman et al.

IMMUNOTHERAPY (2019)

添加到收藏夹
Review Oncology

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Anand Rotte

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹
Review Gastroenterology & Hepatology

Immunotherapy for hepatocellular carcinoma: Current and future

Michael P. Johnston et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹
Review Immunology

Complementing the Cancer-Immunity Cycle

Ruben Pio et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹
Article Oncology

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

M. Moehler et al.

ONCOIMMUNOLOGY (2019)

添加到收藏夹
Review Oncology

Immunotherapy in advanced gastric cancer, is it the future?

C. Coutzac et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

添加到收藏夹
Article Biochemistry & Molecular Biology

Vaccines for colorectal cancer: an update

Mostafa Sarvizadeh et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2019)

添加到收藏夹
Review Biochemistry & Molecular Biology

Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis

Divya Thomas et al.

MOLECULAR CANCER (2019)

添加到收藏夹
Review Biochemistry & Molecular Biology

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Xianjie Jiang et al.

MOLECULAR CANCER (2019)

添加到收藏夹
Article Gastroenterology & Hepatology

The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

Akram Pourshams et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹
Review Gastroenterology & Hepatology

Inflammation and pancreatic cancer: An updated review

Kamleshsingh Shadhu et al.

SAUDI JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹
Article Immunology

Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer

Dachuan Zhang et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹
Review Oncology

Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies

Jesus Rodriguez-Pascual et al.

CANCER DRUG RESISTANCE (2019)

添加到收藏夹
Article Oncology

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

Glen J. Weiss et al.

INVESTIGATIONAL NEW DRUGS (2018)

添加到收藏夹
Article Oncology

Cancer Statistics, 2018

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹
Article Oncology

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Jason Chesney et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹
Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹
Editorial Material Gastroenterology & Hepatology

Elucidating the link between collagen and pancreatic cancer: what's next?

Shin Hamada et al.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2018)

添加到收藏夹
Article Oncology

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial

Charles S. Fuchs et al.

JAMA ONCOLOGY (2018)

添加到收藏夹
Meeting Abstract Oncology

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.

Luigi Buonaguro et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹
Review Biochemistry & Molecular Biology

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics

Karie Runcie et al.

MOLECULAR MEDICINE (2018)

添加到收藏夹
Review Immunology

The Potential of CAR T Cell Therapy in Pancreatic Cancer

Mehmet Akce et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹
Article Multidisciplinary Sciences

The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status

Evangelos Koustas et al.

PLOS ONE (2018)

添加到收藏夹
Review Gastroenterology & Hepatology

Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens

Sandra Wagner et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹
Review Microbiology

Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases

Krupa Naran et al.

FRONTIERS IN MICROBIOLOGY (2018)

添加到收藏夹
Review Oncology

Immunotherapy and pancreatic cancer: unique challenges and potential opportunities

Kate Young et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)

添加到收藏夹
Review Gastroenterology & Hepatology

Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy

Shoichi Hazama et al.

ANNALS OF GASTROENTEROLOGICAL SURGERY (2018)

添加到收藏夹
Article Oncology

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

M. Hidalgo et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2017)

添加到收藏夹
Article Oncology

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients

Akihito Kawazoe et al.

GASTRIC CANCER (2017)

添加到收藏夹
Article Gastroenterology & Hepatology

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

Elizabeth D. Thompson et al.

GUT (2017)

添加到收藏夹
Review Oncology

The colorectal cancer immune microenvironment and approach to immunotherapies

Minoru Koi et al.

FUTURE ONCOLOGY (2017)

添加到收藏夹
Review Oncology

Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)

Kit Man Wong et al.

CURRENT ONCOLOGY REPORTS (2017)

添加到收藏夹
Article Oncology

Molecular classifications of gastric cancers: Novel insights and possible future applications

Silvio Ken Garattini et al.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)

添加到收藏夹
Review Multidisciplinary Sciences

PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis

Lihu Gu et al.

PLOS ONE (2017)

添加到收藏夹
Review Oncology

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer

Omid Hamid et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)

添加到收藏夹
Article Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹
Review Oncology

Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer

Evangelos Koustas et al.

CANCER LETTERS (2017)

添加到收藏夹
Review Oncology

Engineering CAR-T cells

Cheng Zhang et al.

BIOMARKER RESEARCH (2017)

添加到收藏夹
Article Oncology

Cancer treatment and survivorship statistics, 2016

Kimberly D. Miller et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

添加到收藏夹
Review Oncology

Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang

Adriana Amaro et al.

CANCER AND METASTASIS REVIEWS (2016)

添加到收藏夹
Review Gastroenterology & Hepatology

Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma

Christopher C. DuFort et al.

GASTROENTEROLOGY (2016)

添加到收藏夹
Review Immunology

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

David H. Munn et al.

TRENDS IN IMMUNOLOGY (2016)

添加到收藏夹
Review Immunology

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Vinit Kumar et al.

TRENDS IN IMMUNOLOGY (2016)

添加到收藏夹
Article Oncology

Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells

Luana Lugini et al.

ONCOTARGET (2016)

添加到收藏夹
Article Oncology

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

Christine Boeger et al.

ONCOTARGET (2016)

添加到收藏夹
Review Biotechnology & Applied Microbiology

TRUCKs: the fourth generation of CARs

Markus Chmielewski et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2015)

添加到收藏夹
Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹
Article Oncology

Familial Gastric Cancers

Namrata Setia et al.

ONCOLOGIST (2015)

添加到收藏夹
Article Oncology

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

M. Aglietta et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹
Review Immunology

Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects

Yukai He et al.

IMMUNOTHERAPY (2014)

添加到收藏夹
Article Gastroenterology & Hepatology

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

John Bridgewater et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹
Review Biotechnology & Applied Microbiology

Pancreatic cancer, treatment options, and GI-4000

Marion L. Hartley et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)

添加到收藏夹
Review Biotechnology & Applied Microbiology

Vaccines versus immunotherapy: Overview of approaches in deciding between options

Angus G. Dalgleish

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)

添加到收藏夹
Article Oncology

The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance

Douglas T. Fearon

CANCER IMMUNOLOGY RESEARCH (2014)

添加到收藏夹
Review Oncology

Oncolytic viral therapy for pancreatic cancer: current research and future directions

Justin W. Ady et al.

ONCOLYTIC VIROTHERAPY (2014)

添加到收藏夹
Article Multidisciplinary Sciences

Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Christine Feig et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

添加到收藏夹
Review Pharmacology & Pharmacy

Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation

Vincenzo Corbo et al.

CURRENT DRUG TARGETS (2012)

添加到收藏夹
Article Oncology

Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer

Toru Masuzawa et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2012)

添加到收藏夹
Review Biotechnology & Applied Microbiology

Oncolytic vaccinia virus for the treatment of cancer

Kilian Guse et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2011)

添加到收藏夹
Review Immunology

Potential targets for pancreatic cancer immunotherapeutics

Lindzy F. Dodson et al.

IMMUNOTHERAPY (2011)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

Jeong Heo et al.

MOLECULAR THERAPY (2011)

添加到收藏夹
Review Multidisciplinary Sciences

Cancer immunotherapy comes of age

Ira Mellman et al.

NATURE (2011)

添加到收藏夹
Article Oncology

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Milind M. Javle et al.

BMC CANCER (2010)

添加到收藏夹
Article Oncology

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome

Z. Saridaki et al.

BRITISH JOURNAL OF CANCER (2010)

添加到收藏夹
Article Oncology

MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models

Jung-ah Cho et al.

CANCER LETTERS (2009)

添加到收藏夹
Article Oncology

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

Brian M. Wolpin et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹
Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

添加到收藏夹
Article Oncology

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer

Howard L. Kaufman et al.

CLINICAL CANCER RESEARCH (2008)

添加到收藏夹
Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹
Article Oncology

An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study

JA Ajani et al.

CANCER (2006)

添加到收藏夹
Review Oncology

Allergies and the risk of pancreatic cancer: A meta-analysis with review of epidemiology and biological mechanisms

S Gandini et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.